ALK and lung carcinoma: Given that the development of resistance to PEM in ALK-positive cells is associated with the activation of the alternative signaling system, including the HER family, this leads to the possibility that EGFR-HER inhibition will have a therapeutic effect on lung cancer that has acquired PEM resistance.